Home
    Disclaimer
    Pyrazolam molecular structure

    Pyrazolam Stats & Data

    Sh-i-04
    NPS DataHub
    MW354.21
    FormulaC16H12BrN5
    CAS39243-02-2
    IUPAC8-bromo-1-methyl-6-pyridin-2-yl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
    SMILESBrc1ccc2c(c1)C(=NCc1nnc(C)n12)c1ccccn1
    InChIKeyBGRWSFIQQPVEML-UHFFFAOYSA-N
    Benzodiazepines; 2020/3. Benzodiazepine; 2021/3. Benzodiazepine; 2022/3. Benzodiazepine
    Chemical Class Benzodiazepine
    Psychoactive Class Depressant
    Half-Life ~17 hours (reports vary; clinical PK data are scarce)

    Interaction Warnings

    dissociatives

    This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

    stimulants

    It is dangerous to combine benzodiazepines with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of benzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of benzodiazepines will be significantly increased, leading to intensified disinhibition as well as other effects.

    Receptor Profile

    Receptor Actions

    Modulators
    GABA-A receptor positive allosteric modulator (benzodiazepine site)
    Other
    selective for α2 and α3 receptor subtypes

    History & Culture

    Pyrazolam was originally developed during the 1970s by a research team led by Leo Sternbach at Hoffman-La Roche, the pharmaceutical company responsible for discovering many clinically significant benzodiazepines. Despite its initial synthesis during this prolific period of benzodiazepine research, pyrazolam was never pursued for clinical development or pharmaceutical marketing. The compound remained obscure for several decades until it was "rediscovered" and began appearing on the online research chemical market around 2012. The first official analytical report identifying pyrazolam as a novel substance originated from Finland in 2011, with subsequent reports emerging from the United Kingdom in 2012. Since its emergence, pyrazolam has become established as one of several designer benzodiazepines circulating within the research chemical community, valued particularly for its reported anxiolytic selectivity relative to other effects typical of the benzodiazepine class.

    Subjective Effect Notes

    physical: The physical effects of pyrazolam can be broken down into several components which progressively intensify proportional to dosage.

    cognitive: The general head space of pyrazolam is described by many as one of mild sedation and proportionlly intense anxiety suppression. It contains a large number of typical depressant cognitive effects.

    Effect Profile

    Curated + 9 Reports
    Benzodiazepine 6.9

    Strong anxiolysis and cognitive impairment with moderate euphoria, mild sedation

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    5
    Motor / Cognitive Impairment×1
    8
    Euphoria / Mood Lift×1
    6

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    ~17 hours (reports vary; clinical PK data are scarce)
    Addiction Potential
    Comparable to other benzodiazepines: risk of psychological and physical dependence increases with frequent or high-dose use. New/illicit benzodiazepines are specifically highlighted by EUDA/EMCDDA as a public-health concern (availability, heavy use, and severe poisonings when combined with other depressants).

    Tolerance Decay

    Full tolerance 3d Half tolerance 7d Baseline ~21d

    As with other benzodiazepines, tolerance to sedative/hypnotic effects can build within days of repeated dosing; anxiolytic tolerance may develop more gradually. Rough recovery to baseline often requires several weeks off. Estimates here are conservative and based on general benzo patterns and user reports, not controlled studies.

    Cross-Tolerances

    Other benzodiazepines
    80% ●○○
    Z-drugs (e.g., zolpidem)
    40% ●○○

    Experience Report Analysis

    Erowid
    9 Reports
    2012–2026 Date Range
    9 With Age Data
    7 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 9 experience reports (9 Erowid)

    9 Reports
    7 Effects Detected
    5 Positive
    2 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 5

    Anxiety Suppression 77.8% 70%
    Sedation 66.7% 70%
    Euphoria 55.6% 70%
    Stimulation 55.6% 70%
    Color Enhancement 33.3% 70%

    Adverse Effects 2

    Muscle Tension 33.3% 70%
    Increased Heart Rate 33.3% 70%

    Real-World Dose Distribution

    62K Doses

    From 215 individual dose entries

    Oral (n=204)

    Median: 0.75mg 25th: 0.75mg 75th: 0.75mg 90th: 0.75mg
    mg/kg median: 0.008 mg/kg 75th: 0.008

    Form / Preparation

    Most common forms and preparations reported

    Benzodiazepine Equivalence

    2.0 mg Pyrazolam = 10.0 mg Diazepam
    Potency ratio 5.0

    Pyrazolam - 1-2mg ~=10mg Diazepam.

    Legal Status

    Country Status Notes
    Canada Schedule IV (CDSA) Controlled under the Controlled Drugs and Substances Act as part of the blanket scheduling of all benzodiazepines. Possession, trafficking, and production without authorization carry criminal penalties.
    Germany NpSG controlled Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalty.
    Russia Schedule III Listed as a Schedule III controlled substance since 2017. Production, distribution, and possession are regulated under federal drug control legislation.
    Sweden Controlled substance Classified as a controlled narcotic substance under Swedish drug legislation. Possession, sale, and distribution are prohibited.
    Switzerland Verzeichnis E Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation. Unauthorized possession and distribution are prohibited.
    Turkey Illegal Classified as an illegal drug under Turkish drug control laws. Possession, production, supply, and importation are all criminal offenses.
    United Kingdom Class C Controlled as a Class C substance under the Misuse of Drugs Act 1971 since May 31, 2017. Prior to this, a Temporary Class Drug Order (TCDO) issued in December 2016 had already prohibited personal possession, not just import and supply. It is illegal to possess, produce, or supply.

    Harm Reduction

    drugs.wiki

    • Potency is in the low milligram range, increasing the risk of accidental over- or redosing if pellets/liquids are mislabelled or non-uniform; multiple user reports since 2024–2025 describe “pyrazolam” products that appeared to be norflurazepam or otherwise inconsistent—use drug checking where possible and treat new batches as unknown potency. • The come-up can be slower and more gradual than many expect; some users don’t feel full effects until ~2–3 hours. Avoid redosing early; wait at least 2–3 hours before considering more to reduce blackout risk. • Like other benzodiazepines, pyrazolam can cause anterograde amnesia, impaired coordination, and “functionality illusions” (feeling calm while motor skills and judgment are impaired). Do not drive or perform safety-critical tasks. • Combining with other depressants (alcohol, opioids, GHB/GBL, barbiturates, Z‑drugs) greatly increases overdose risk via additive respiratory depression; harm-reduction groups flag benzo–opioid combos as a key driver of poisonings. • Dependence and difficult withdrawal (including seizures) are documented across the new/illicit benzodiazepines category; avoid frequent use and do not stop abruptly after extended use—seek medical guidance for tapering. • Given the variability and mislabeling in this market, volumetric dosing (dissolving a known quantity into a measured volume and dosing by volume) can reduce dose error; TripSit provides a calculator and guidance. • Some community reports claim pyrazolam dissolves readily in water; others note pH-dependent solubility similar to midazolam. Treat solubility claims cautiously; if making solutions, use appropriate solvents/containers and label clearly to prevent accidental ingestion. • Designer/illicit benzodiazepines are sometimes found in opioid samples (“benzo-dope”); if using opioids, assume possible benzo co-exposure and carry naloxone—but note naloxone does not reverse benzodiazepines. • Legal status varies and can change quickly. In the UK and many EU countries, new benzodiazepines including pyrazolam have been targeted by controls; possession/supply may be illegal. • Amnestic effects increase steeply with dose and with combinations; users report blackouts at higher doses or with stacked redoses—consider a trusted sober sitter if experimenting.

    ← Back to Pyrazolam